z-logo
open-access-imgOpen Access
Comment on: Atkinson. It's Time to Consider Changing the Rules: The Rationale for Rethinking Control Groups in Clinical Trials Aimed at Reversing Type 1 Diabetes. Diabetes 2011;60:361–363
Author(s) -
Srinath Sanda,
Carla J. Greenbaum
Publication year - 2011
Publication title -
diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.219
H-Index - 330
eISSN - 1939-327X
pISSN - 0012-1797
DOI - 10.2337/db11-0253
Subject(s) - clinical trial , pace , reversing , argument (complex analysis) , medicine , type 2 diabetes , diabetes mellitus , alternative medicine , placebo , natural history , intensive care medicine , pathology , endocrinology , materials science , geodesy , composite material , geography
Although in his recent editorial Atkinson (1) made a persuasive argument to consider alternative trial designs for type 1 diabetes, we are in disagreement with the suggestion that placebo-controlled trials are no longer needed in studies evaluating therapies to alter the natural history of type 1 diabetes in recently diagnosed subjects.Many of the frustrations about the pace of discovery felt by patients, families, and researchers confuse the actual facts about clinical trials. Although it is true that enrollment in clinical trials overall is difficult and hampers the national imperative to translate basic science to clinical care, clinical trials in …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom